Pulmonology

Journal Club ft. NEJM publications

Questions discussed in this category

Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?

Does the severity of asthma play a role in decision making?

2 Answers available

Do you utilize cytokine panels to guide treatment of patients with EGPA?

2 Answers available

Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?

1 Answer available

How do you identify which patients are at highest risk for decompensation and most likely to benefit from NIV for pre-oxygenation prior to intubation?

2 Answers available

Does the experience level of the intubation operator affect outcomes related to pre-oxygenation with NIV versus an oxygen mask?

2 Answers available

Does the use of NIV for pre-oxygenation delay the time to intubation?

2 Answers available

What are the logistical challenges and time constraints of implementing NIV for pre-oxygenation in emergency settings compared to oxygen masks?

1 Answer available

Would bag-mask ventilation with a PEEP valve be a reasonable alternative to NIV for pre-oxygenation prior to intubation in settings where NIV is not easily accessible?

1 Answer available

Is there a subset of patients in whom pre-oxygenation with NRB or BVM could be safely pursued?

1 Answer available

What patient factors prompt you to consider starting dupilumab in patients with COPD?

Does active smoking status influence this decision?

2 Answers available

Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?

2 Answers available

Are the results of the BOREAS trial generalizable to non-white populations?

The cohort in the study was predominantly white. Do these results highlight significant disparities in COPD care?

2 Answers available

Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?

If so, would this be a consideration in all patients regardless of active smoking status? FeNO in active smokers has been questioned, could this have ...

2 Answers available

How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

5 Answers available

What strategies can be employed to manage interstitial lung disease seen with trastuzumab deruxtecan?

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use? Do you feel the dosing used in...

2 Answers available

Papers discussed in this category

Cancer Treat Rev, 2022 Mar 12

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

The New England journal of medicine, 2024 Jun 13

Noninvasive Ventilation for Preoxygenation during Emergency Intubation.

Critical care medicine, 2019 Apr

Compared Efficacy of Four Preoxygenation Methods for Intubation in the ICU: Retrospective Analysis of McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope (MACMAN) Trial Data.

European journal of anaesthesiology, 2015 Dec

Preoxygenation by spontaneous breathing or noninvasive positive pressure ventilation with and without positive end-expiratory pressure: A randomised controlled trial.

The American journal of emergency medicine, 2016 May 28

The utility of noninvasive nasal positive pressure ventilators for optimizing oxygenation during rapid sequence intubation.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Dec 30

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

European journal of clinical investigation, 2024 Oct 10

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies.

Clinical and experimental rheumatology, 2019

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

PloS one, 2015 Mar 26

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Frontiers in immunology, 2022 Jun 10

Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.

Rheumatology (Oxford, England), 2025 Mar 01

SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment.

The Journal of allergy and clinical immunology, 2022 Jun 27

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Related Topics in Pulmonology